 Latest News
CTP and NIDA Announce the Continuation of the Population Assessment of Tobacco and Health (PATH) Study
On February 5, 2024, the FDA’s Center for Tobacco Products (CTP) and NIH’s National Institute on Drug Abuse (NIDA) announced the continuation of the Population Assessment of Tobacco and Health (PATH) Study through the award of a contract to Westat. The continuation of the PATH Study, through this third contract, provides further opportunities for researchers to use study data to advance knowledge about tobacco use and its impact on health.
CTP Releases Five-Year Strategic Plan
On December 18, 2023, CTP Director Brian King published a statement about the release of the center’s comprehensive strategic plan. The new strategic plan outlines CTP’s programmatic and workforce initiatives for the next five years.
CTP’s Strategic Plan defines five goals, 10 outcomes, and several corresponding objectives. As outlined in the goals and outcomes in the plan, the center is collectively committed to issuing impactful regulations, using robust science to inform application reviews, pursuing timely and impactful compliance and enforcement strategies, and educating the public about the risks of tobacco products. CTP will also continue to invest in staff by advancing operational enhancements and supporting the further development of the center’s highly qualified, inclusive, and high-performing workforce.
Presentation Recordings Now Available from FDA’s Public Meeting on Premarket Application Processes for Tobacco Products
Recordings from FDA’s October 23-24, 2023, public meeting on the premarket application processes for new tobacco products, including substantial equivalence (SE) reports and premarket tobacco product applications (PMTAs), are now available online. This includes individual videos of all 14 presentations, Q&A with scientific staff, as well as opening and closing remarks. Transcripts for each day are also available.
Renewal Applications Filed for Swedish Match USA’s Modified Risk Tobacco Products
On November 30, 2023, FDA filed for scientific review modified risk tobacco product (MRTP) renewal applications submitted by Swedish Match USA for General Snus smokeless tobacco products.
PMTA Decisions
FDA continues to make decisions on PMTAs, including the following:
-
February 5, 2024: Marketing Denial Order Fontem US, LLC (blu Disposable)
-
January 22, 2024: Marketing Denial Order Bidi Vapor LLC (Bidi Stick—Classic)
-
January 19, 2024: Marketing Denial Orders Shenzhen Youme Information Technology Co. Ltd. (Suorin) and Fontem US, LLC (blu PLUS+)
-
January 16, 2024: Marketing Denial Orders Shenzhen IVPS Technology Co., Ltd (SMOK)
More About CTP Research
Current Funding Opportunities
- Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - RFA-OD-22-023 or RFA-OD-22-024)
- Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - RFA-OD-22-025 (non-clinical trial) or RFA-OD-22-026 (clinical trial))
- Tobacco Regulatory Science (R01 Clinical Trial Optional - RFA-OD-23-017)
- FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science (FDABAA-24-00123)
- FDA Support for Conferences and Scientific Meetings (R13 - PAR-23-072)
Recent Publications by CTP Researchers
- Changes in industry marketing of electronic nicotine delivery systems on social media following FDA's prioritized enforcement policy: a content analysis of Instagram and Twitter posts
- Believability of messaging concerning a hypothetical product standard to lower a constituent in cigarettes or smokeless tobacco among U.S. Adults who use tobacco
- Smoking cessation prevalence by menthol cigarette use and select demographics among adults in the United States, TUS-CPS, 2003-2019
- Smoke exposure associated with higher urinary benzene biomarker muconic acid (MUCA) in Golestan Cohort Study participants
- Use patterns of flavored non-cigarette tobacco products among US adults, 2010–2019
- Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study.
- Use of E-Cigarettes and Cigarettes During Late Pregnancy Among Adolescents.
- Relationship Between Tobacco Product Use and Health-Related Quality of Life Among Individuals With COPD in Waves 1-5 (2013-2019) of the Population Assessment of Tobacco and Health Study.
- Trends in Smoking Before, During, and After Pregnancy in the United States from 2000 to 2020: Pregnancy Risk Assessment Monitoring System.
- Cardiovascular disease outcomes among established cigar users 40 years and older: Findings from the population assessment of tobacco and health (PATH) study, waves 1-5 (2013-2019)
- Tobacco-Specific Nitrosamines in Current Commercial Large Cigars, Cigarillos, and Little Cigars
- Trends and Associations of Past-30-Day Cigar Smoking in the U.S. by Age, Race/Ethnicity, and Sex, NSDUH 2002-2020.
- Changes in Tobacco Dependence and Association With Onset and Progression of Use by Product Type From Waves 1 to 3 of the Population Assessment of Tobacco and Health (PATH) Study.
- Environmental persistence, bioaccumulation, and hazards of chemicals in e-cigarette e-liquids: short listing chemicals for risk assessment
- Tobacco Product Use Among U.S. Middle and High School Students - National Youth Tobacco Survey, 2023.
- US FDA public meeting: identification of concepts and terminology for multicomponent biomarkers.
- On-Chip Reconstitution of Uniformly Shear-Sensing 3D Matrix-Embedded Multicellular Blood Microvessel
- State-Specific Prevalence of Adult Tobacco Product Use and Cigarette Smoking Cessation Behaviors, United States, 2018-2019.
 |
This newsletter serves as a digest of the latest announcements and stories out of CTP. It is a complement to our CTP Connect newsletter and CTP News e-blasts.
|
